Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Jennifer Brown on Gauging Response in CLL

February 20th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses gauging response in chronic lymphocytic leukemia.

Ibrutinib Receives Breakthrough Designations for Mantle Cell Lymphoma and WaldenstrÃ¶m's Macroglobulinemia

February 13th 2013

The investigational agent ibrutinib was granted "Breakthrough Therapy Designations" by the FDA as a singular therapy for a pair of B-cell malignancies: relapsed or refractory mantle cell lymphoma and WaldenstrÃ¶m's macroglobulinemia.

Dr. Francesco Lo-Coco on Arsenic Trioxide in APL

February 13th 2013

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide (ATO), in acute promyelocytic leukemia (APL).

Biotech Focus: Tracking the Oncology Pipeline

February 13th 2013

Several updates highlighted at the 2012 American Society of Hematology Annual Meeting as well as other developments.

Dr. Fanale on the Potential of Antibody-Drug Conjugates

February 12th 2013

Michelle A. Fanale, MD, from the MD Anderson Cancer Center, discusses the potential of antibody-drug conjugates, as a new category of therapy for patients with cancer.

Dr. Lo-Coco on Arsenic Trioxide in Acute Promyelocytic Leukemia

February 12th 2013

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide, in acute promyelocytic leukemia.

Dr. Berenson on Pomalidomide Plus Doxil in Multiple Myeloma

February 6th 2013

James R. Berenson, MD, discusses a phase I/II study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma.

Dr. Cortes Discusses Ponatinib as Initial Therapy for CML

February 5th 2013

Jorge E. Cortes, MD, Department of Leukemia, University of Texas, MD Anderson Cancer Center, discusses the use of ponatinib as initial therapy for patients with chronic myeloid leukemia.

Obinutuzumab Significantly Improves PFS in CLL

January 31st 2013

The first set of results from a phase III clinical trial found that obinutuzumab plus chlorambucil chemotherapy significantly improved PFS in patients with CLL.

Dr. Fanale on Brentuximab Vedotin in High-Risk ALCL

January 30th 2013

Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of brentuximab vedotin as frontline treatment of systemic anaplastic large cell lymphoma.

Study Suggests Patient Age Should Factor Into CLL Treatment Selection

January 30th 2013

Research from the Ohio State University Comprehensive Cancer Center suggests that chlorambucil may be better than fludarabine in treating older patients with CLL, and that rituximab is beneficial regardless of age.

Dr. John Byrd on Bruton's Tyrosine Kinase in CLL

January 29th 2013

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's Tyrosine Kinase (BTK) in chronic lymphocytic leukemia.

Dr. Erba on Azacitidine and Gemtuzumab Ozogamicin

January 23rd 2013

Harry Erba, MD, PhD, discusses the results of a phase II study analyzing azacitidine and gemtuzumab ozogamicin as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 AML.

Dr. Jagannath on Life Expectancy in Myeloma

January 22nd 2013

Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, details the advances in life expectancy for patients with multiple myeloma.

Dr. Zaks on the JAK2 Inhibitor SAR302503 in Myelofibrosis

January 21st 2013

Tal Zaks, MD, PhD, Sanofi Oncology, details a phase II randomized study of the JAK2 inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF.

Dr. Furman on Trials Examining Ibrutinib's Safety in CLL

January 18th 2013

Richard R. Furman, MD, from the Weill Cornell Medical Center, discusses the safety profile of the oral BTK inhibitor ibrutinib in both relapsed/refractory and treatment naive patients with chronic lymphocytic leukemia.

Dr. McCarthy on Eligibility Criteria for Allogeneic BMT

January 18th 2013

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, explains the factors that determine patient tolerability to allogeneic bone marrow transplant.

Dr. Smita Bhatia on Anthracycline-Related CHF

January 17th 2013

Smita Bhatia, MD, MPH, Population Sciences, City of Hope, Duarte, California, explains a clinical trial analyzing genetic susceptibility to anthracycline-related congestive heart failure in survivors of hematopoietic cell transplantation.

Making Oncology History: Imatinib Pioneer Created His Own Opportunities

January 17th 2013

Brian J. Druker, MD, one of the pioneering researchers who discovered imatinib, has maintained his focus on finding new and better treatments for CML and other leukemias.

Dr. Fanale on Frontline Brentuximab in Lymphoma

January 16th 2013

Michelle A. Fanale, MD, from the MD Anderson Cancer Center, discusses a phase I trial that examined the frontline administration of brentuximab vedotin for patients with subtypes of lymphoma.